

Reviewer Relationships With Industry and Other Entities (Comprehensive) — 2019 Heart House Roundtables Methodology

Reviewer	Representation	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
C. Michael Valentine	Official Reviewer—ACC President	Stroobants Cardiovascular Center of Centra Health—Senior Cardiologist; American College of Cardiology, President	None	None	None	None	None	None
James L. Januzzi, Jr.	Official Reviewer—Task Force on Expert Consensus Decision Pathways	Massachusetts General Hospital—Director, Dennis and Marilyn Barry Fellowship in Cardiology Research Cardiology Division; Harvard Medical School—Hutter Family Professor of Medicine	<ul style="list-style-type: none"> • Abbott • Critical Diagnostics* • Philips • Roche Diagnostics* 	None	None	<ul style="list-style-type: none"> • AbbVie (DSMB)* • Amgen (DSMB)* • Boehringer Ingelheim (DSMB)* • Cleveland Heart Labs* • Janssen Pharmaceuticals (DSMB)* • Novartis* • Prevensio* • Siemens* • Singulex* 	None	None
Vinay Badhwar	Content Reviewer—Roundtable Planning Committee	WVU Heart and Vascular Institute—Gordon F. Murray Professor and Executive Chair; West Virginia University School of Medicine—Service Line Chief, Division of Cardiothoracic Surgery	None	None	None	None	<ul style="list-style-type: none"> • Teledyne‡ 	None
Ana Barac	Content Reviewer—Cardio-Oncology Section Leadership Council	Medstar Heart and Vascular Institute Associate Professor of Medicine, Georgetown University—Director, Cardio-oncology Program	None	None	None	None	<ul style="list-style-type: none"> • Boston Scientific†‡ 	None

Lee R. Goldberg	Content Reviewer— Section Steering Committee	University of Pennsylvania—Medical Director, Heart Failure and Transplantation Program; Hospital of the University of Pennsylvania— Associate Professor	<ul style="list-style-type: none"> • Medtronic • Novartis • Respicardia 	None	None	<ul style="list-style-type: none"> • NIH† • Respicardia† 	None	None
Eileen M. Handberg	Content Reviewer— Cardiovascular Team Section Leadership Council	University of Florida— Research Professor of Medicine; Director, Clinical Trials Program; Florida CARES & CAP— Program Director	<ul style="list-style-type: none"> • Bristol-Myers Squibb 	None	None	<ul style="list-style-type: none"> • Aastrom Biosciences* • Amorceyte* • BioCardia* • Brigham and Women’s Hospital* • Capricor* • Cytori Therapeutics* • DCRI* • Department of Defense* • Direct Flow Medical* • East Carolina University* • Everyfit Inc. * • Medtronic* • Merck* • Mesoblast Inc. * • NIH* • NIH through Brigham and Women’s Health* • NIH through University of Rochester* • NIH through University of Texas* • PCORI* • Sanofi-Aventis* 	<ul style="list-style-type: none"> • Amgen • AstraZeneca • Boehringer Ingelheim • Daiichi Sankyo • Gilead Sciences • Ionis Pharmaceuticals • Relypsa 	None

William Hucker	Content Reviewer— Roundtable Planning Committee	Massachusetts General Hospital—Fellow in Cardiovascular Medicine	None	None	None	None	None	None
Dharam J. Kumbhani	Content Reviewer— Task Force on Health Policy Statements and Systems of Care	UT Southwestern Medical Center—Assistant Professor, Interventional Cardiology, Department of Internal Medicine	• ACC*	None	None	None	None	None
Glenn N. Levine	Content Reviewer— Official Reviewer— ACC/AHA Task Force on Clinical Practice Guidelines, Chair	Baylor College of Medicine—Master Clinician and Professor of Medicine; Michael E. DeBakey Medical Center— Director, Cardiac Care Unit	None	None	None	None	None	<ul style="list-style-type: none"> • Defendant, Out of hospital cardiopulm onary arrest, 2017* • Defendant, Out of hospital death, 2018*
Thomas M. Maddox	Content Reviewer— Science and Quality Committee	Washington University School of Medicine/BJC Healthcare—Director, Health Systems Innovation Lab (HSIL); Washington University School of Medicine—Professor of Medicine (Cardiology)	None	None	None	None	None	None
Laxmi S. Mehta	Content Reviewer— Science and Quality Committee	The Ohio State University Medical Center—Clinical Director of the Women's Cardiovascular Health Program; Associate Program Director for Education, Center for Women's Health; Assistant Professor of Internal Medicine	None	None	None	None	• AHA†	None
Andrea M. Russo	Content Reviewer— Roundtable Planning Committee	Cooper Medical School of Rowan University— Professor of Medicine;	<ul style="list-style-type: none"> • Biotronik • Boston Scientific • Medtronic 	None	None	<ul style="list-style-type: none"> • BardyDx • Boehringer Ingelheim* 	<ul style="list-style-type: none"> • ACC† • Biotronik† • HRS† 	None

		Director, Cardiac Electrophysiology and Arrhythmia Services; Director; CCEP Fellowship	<ul style="list-style-type: none"> • St. Jude Medical • Up-To-Date 			<ul style="list-style-type: none"> • Boston Scientific* • Medtronic* 	<ul style="list-style-type: none"> • Medtronic* 	
Sarah A. Spinler	Content Reviewer—Roundtable Planning Committee	Philadelphia College of Pharmacy University of the Sciences in Philadelphia—Professor of Clinical Pharmacy	<ul style="list-style-type: none"> • Portola Pharmaceuticals • Regeneron 	<ul style="list-style-type: none"> • Bristol-Myers Squibb 	None	None	None	None
Eric Stecker	Content Reviewer—Science and Quality Committee and Prevention Section Leadership Council	Knight Cardiovascular Institute, Oregon Health & Science University—Associate Professor of Medicine	None	None	<ul style="list-style-type: none"> • Hygeia/Desi MD* 	<ul style="list-style-type: none"> • AHA* • Medical Research Foundation of Oregon* 	<ul style="list-style-type: none"> • ARCA Biopharma‡ • SentreHEART‡ 	None
L. Samuel Wann	Content Reviewer—Roundtable Participant	Ascension Healthcare—Cardiologist	None	None	None	None	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$5,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC Disclosure Policy for Writing Committees.

* Significant relationship.

† No financial benefit.

‡ Relationship with this company is limited to enrolling patients in clinical trials. This disclosure was entered under the Clinical Trial Enroller category in the ACC's disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the ACC/AHA Disclosure Policy for Writing Committees.

ACC=American College of Cardiology; AHA=American Heart Association; CAP= Competency Advancement Program; CARES=Comprehensive Assessment and Remedial Education Services; CCEP=Certified Compliance and Ethics Professional; DCRI=Duke Clinical Research Institute; DSMB=Data Safety Monitoring Board; HRS=Heart Rhythm Society; NIH=National Institutes of Health; PCORI=Patient-Centered Outcomes Research; UT=University of Texas; WVU=West Virginia University;